step tavr growth low-risk
edward report rev slightli higher consensu
estim world-wide tavr rev surpris upsid vs
estim sequenti step tavr number combin
pull-forward low-risk approv time bound give anoth reason
stock stretch multipl even maintain rate slightli
tweak pt fulli recogn pt current stock price
tavr grew y/i tavr growth high-teen ou
mid-teen rang math seem indic tavr came
ou compani said edward procedur growth in-
line market share remain stabl despit price
 premium corevalv step-up notabl given
qtr mark consecut qtr market procedur growth
edward suddenli qtr thing tick unclear key driver
sequenti step-up sustain step-up
compani announc one-tim charg write centerra
inventori compani made strateg decis discontinu centerra
given invest need gain addit label field check
well recent dear letter dont jibe compani commentari
state past true valu proposit centerra sapien
ultra price premium sapien clear us
 rate receiv pma approv lotu edg
tavr valv yesterday open new competit front
abbott rate entri later portico approv bound
pressur edward tavr share even
low-risk pma approv come earlier expect worri
indic creep alreadi occur increment gain could limit
edward tmtt segment gener qtr tmtt guidanc
maintain need huge step tmtt
compani commentari seem hedg pascal sapien
posit predispos edward long-term fundament howev
headlin low-risk approv behind us worri tavr
growth rate go hard time meet expect viabil
edward mitral program quit far even abbott prevail ip
infring battl henc stuck rock hard place
earlier valu tavr piec busi sale tweak
multipl justifi pt increas howev confess stock
trade beyond perfect
ew report number slightli consensu estim tavr
world-wide number beat estim stark revers number
rel soft unclear sequenti step due pull-through post-partn excit within
 new geographi japan util uptick within europ quarter compani
stop provid tavr split ou number although state growth impli us tavi
rev came gaap tavi sale non-gaap tavi sale royalti sale
return reserv vs estim math suggest tavi sale y/i as-
report basi impli ou tavi rev seem rang y/i world-wide tavr sale
y/i admittedli edwardss commentari procedur growth market share littl confus us
compani state asp stabl across region charg quarter due
compani decis discontinu market centerra valv gm adjust one-tim inventori
charg would in-lin estim compani commentari impli market procedur
growth high-teen ou mid-teen edward growth rate in-lin
market gradual shift provid specif market vs edward growth rate continu muddi
proper analys contribut japan remain unclear compani indic maintain tavr share
quarter although confess real growth rate exclud higher asp sapien ultra exactli clear
us compani decid discontinu centerra launch rational cite extra cost need gain
addit indic approv dear letter centerra well field check jibe
thing mention note
call edward indic competitor still compet price although edward
maintain price point rational given sapien except outcom
make strateg sens engag price war state multipl time past edward ou
share closer rang almost coupl year ago edward state
past sapien ultra centerra would help move price point even higher
centerra pictur sapien ultra convers global expect complet
end unclear price premium sapien ultra garner would need factor
nomin growth tavr unclear contribut ou tavr
growth come de novo implant vs price premium sapin ultra said
note unclear valu proposit centerra sapien ultrawil improv procedur
time enough justifi increas asp improv outcom drastic justifi increas
asp count seriou doubt market support even higher price point
page
interestingli deliveri system sapien ultra seem encount pushback field
led edward incorpor sapien deliveri system onto sapien ultra deliveri
one fundament question see rais field nowaday threshold
switch cost becom manag edward reli larg extent expand label
breadth product offer presenc one competitor current leadership statu new
competitor launch lotu valv even edward admit
carri good launch move forward given edward go
lose share boston law larg number indic combin market leadership posit
well price premium sapien present hurdl time edward nomin growth
rate essenti forc clinician choos player
certain extent fundament competit dynam balanc low-risk approv
expect sometim big question move forward remain increment growth
post-approv one seem clear answer importantli continu fundament
question averag age patient yr low-risk label sapien
look like control age drift yr stroke patient younger becom critic featur
edward commentari seem indic share loss below-market procedur growth
edward edward suddenli seem par market unclear much
sequenti bump temporari euphoria outcom
growth high-teen ou procedur growth edward in-lin market growth
remind care need exercis extrapol procedur growth sale growth
ou edward given price premium
compani clarifi exact contribut intermediate-risk especi us util
rate shown wherea ou rang ou procedur volum
bare budg last quarter embed within number contribut japan
would fascin sift util rate japan vs europ unfortun
number edward provid contribut japan annual guidanc also
figur approx tavr procedures/day geographi
page
edward past indic us tavr growth come littl center
although number new center quarter state dont number would
fascin deep-div sales-rep product stratifi volum procedur per center
contribut tavr sale uk state remind guidelin recent call
expand use tavr
final ncd tavr state net posit although time tell edward remain confid
wont materi chang polici would hinder broad adopt
tmtt sale
edward transcath mitral repair product pascal ce mark total tmtt sale quarter
compani provid split cardioband pascal europ unclear
us type center adopt use pascal type patient implant
pascal get chanc ask question quarterli call would love know
center exist pascal ce trial center mitraclip patient cannib pascal
would even fascin analysi rational clinician pascal mitraclip
least base current evid rational clear us
 edward pivot trial pascal degen mr on-going remind
random patient non-inferior studi dmr compar abbott mitraclip
abbott current seek injunct pascal edward commentari seem impli
injunct highli unlik although contend quit possibl edward ip might found
infring mitraclip ip lead revers scenario fight edward
year ago
biggest surpris call shift low-risk approv later cap
on-going although contribut compani temper expect ramp low-
harpoon edward echo-guid beat heart tmtt product launch later harbor seriou
doubt product
increment updat tricuspid opportun confess core focu
figur approx tavi sale geographi mm
page
world-wide tavi sale higher end guidanc critic guidanc
surgic heart valv guidanc tmtt pascal contribut
cardioband overal revenu guidanc higher end
gross margin expect rang adjust ep rais
primari driver y/i ep growth seem tax benefit expect tax rate
 sale sg sale
figur approx util metric world-wide basi
like edward long-term fundament stori howev struggl find catalyst would drive step
perform current expect stock pt dont confid edward
transcathet mitral endeavor least base current evid rais rate pt use
rational approx tavi sale non-tavi biz tmvr piec fulli recogn pt
current stock price fundament love edward stori hard justifi higher pt till
viabil mitral program establish
page
statement oper
number mm round
good sold
chang fv cont liab
sg
page
edward lifesci world leader surgic heart valv sapien platform transcathet heart valv
also current posit world
pt deriv use sum part methodolog
risk achiev price target
suraj kalia certifi view express report accur reflect person view
subject compani secur part compens directli
indirectli relat specif recommend view express report
